At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs.
The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.

Biotechnology

DICE Therapeutics

J. Kevin Judice

Christian Puccetti

Christy Shoung

Ram Devarapalli

Paula Opal

Jeffrey Enejosa, MD

Mary Riley

Nico Ghilardi

Venkat Thalladi

John Jacobsen

Tim Lu

Scott Robertson

Research and Development

Clinical Operations and Support

Board and Executive Management

Leadership Team

Accounting and Finance

Technology and Operations

Human Resources Team

Regulatory and Compliance

Teams at DICE Therapeutics

Research and Development

Clinical Operations and Support

Board and Executive Management

Leadership Team

Research and Development

Accounting and Finance

Technology and Operations

Human Resources Team

Regulatory and Compliance